BRAF and melanoma: Later, FDA approved Trametinib, which is different from the first two in that it is a MEK inhibitor, and the MEK and mutant BRAF share a partially overlapping signaling pathway, the MEK inhibitors can also be used in the treatment of BRAF mutation of melanoma patients (Leonowens et al., 2014).